Press Release: Dr. Kwatra submits R01 grant to the NCI for his study entitled “Phase II trial of osimertinib in newly diagnosed GBM patients expressing EGFRvIII.”

Dr. Madan Kwatra, Director of Glioblastoma Drug Discovery Group, is pleased to announce his recent R01 grant submission to the National Cancer Institute for 4 million dollars over 5 years. This grant will be used to fund a phase II clinical trial of osimertinib (AZD9291) in newly diagnosed EGFRvIII+ glioblastoma patients. This trial is in collaboration with Wake Forest School of Medicine, Johns Hopkins School of Medicine, and University of Alabama at Birmingham.

Leave a Reply

Your email address will not be published.